Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia : A double-blind, randomized, placebo-controlled trial
© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd..
AIM: The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia.
METHODS: In this randomized, placebo-controlled study, eighty outpatients with chronic schizophrenia were given risperidone for 8 weeks along with either pentoxifylline or a placebo. The positive and negative syndrome scale (PANSS) was used to assess patients at the start of the trial, as well as at 2, 4, 6, and 8 weeks. Pre- and posttreatment serum levels of cAMP, TNF-α-, and IL-6 were measured.
RESULTS: The pentoxifylline group revealed a significant effect for time-treatment interaction on PANSS-negative subscale scores (p < 0.001), PANSS general psychopathology subscale scores (p < 0.001), and PANSS total scores (p < 0.001), but not on PANSS-positive subscale scores (p = 0.169). Additionally, when compared to the placebo group, the pentoxifylline group demonstrated a statistically significant increase in cAMP serum level and a statistically significant decrease in TNF-α and IL-6 serum levels.
CONCLUSION: Pentoxifylline adjunctive therapy with risperidone for 8 weeks was found to be promising in mitigating the negative symptoms in patients with chronic schizophrenia.
TRIAL REGISTRATION NUMBER: NCT04094207.
| Errataetall: |
RetractionIn: CNS Neurosci Ther. 2024 Mar;30(3):e14668. - PMID 38465469 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
CNS neuroscience & therapeutics - 29(2023), 1 vom: 13. Jan., Seite 354-364 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdallah, Mahmoud S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.01.2023 Date Revised 11.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT04094207 RetractionIn: CNS Neurosci Ther. 2024 Mar;30(3):e14668. - PMID 38465469 Citation Status MEDLINE |
|---|
| doi: |
10.1111/cns.14010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348555571 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348555571 | ||
| 003 | DE-627 | ||
| 005 | 20240311231820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cns.14010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM348555571 | ||
| 035 | |a (NLM)36341700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdallah, Mahmoud S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia |b A double-blind, randomized, placebo-controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2023 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04094207 | ||
| 500 | |a RetractionIn: CNS Neurosci Ther. 2024 Mar;30(3):e14668. - PMID 38465469 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. | ||
| 520 | |a AIM: The aim of this study was to explore the effectiveness and safety of pentoxifylline as an adjuvant to risperidone in mitigating the negative symptoms in patients with chronic schizophrenia | ||
| 520 | |a METHODS: In this randomized, placebo-controlled study, eighty outpatients with chronic schizophrenia were given risperidone for 8 weeks along with either pentoxifylline or a placebo. The positive and negative syndrome scale (PANSS) was used to assess patients at the start of the trial, as well as at 2, 4, 6, and 8 weeks. Pre- and posttreatment serum levels of cAMP, TNF-α-, and IL-6 were measured | ||
| 520 | |a RESULTS: The pentoxifylline group revealed a significant effect for time-treatment interaction on PANSS-negative subscale scores (p < 0.001), PANSS general psychopathology subscale scores (p < 0.001), and PANSS total scores (p < 0.001), but not on PANSS-positive subscale scores (p = 0.169). Additionally, when compared to the placebo group, the pentoxifylline group demonstrated a statistically significant increase in cAMP serum level and a statistically significant decrease in TNF-α and IL-6 serum levels | ||
| 520 | |a CONCLUSION: Pentoxifylline adjunctive therapy with risperidone for 8 weeks was found to be promising in mitigating the negative symptoms in patients with chronic schizophrenia | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT04094207 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Retracted Publication | |
| 650 | 4 | |a PANSS | |
| 650 | 4 | |a inflammatory cytokines | |
| 650 | 4 | |a negative symptoms | |
| 650 | 4 | |a pentoxifylline | |
| 650 | 4 | |a phosphodiesterase inhibitor | |
| 650 | 4 | |a schizophrenia | |
| 650 | 7 | |a Risperidone |2 NLM | |
| 650 | 7 | |a L6UH7ZF8HC |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Pentoxifylline |2 NLM | |
| 650 | 7 | |a SD6QCT3TSU |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 700 | 1 | |a Mosalam, Esraa M |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Ramadan, Ahmed N |e verfasserin |4 aut | |
| 700 | 1 | |a Omara-Reda, Hend |e verfasserin |4 aut | |
| 700 | 1 | |a Zidan, Abdel-Aziz A |e verfasserin |4 aut | |
| 700 | 1 | |a Samman, Waad A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Berri, Eman I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS neuroscience & therapeutics |d 2008 |g 29(2023), 1 vom: 13. Jan., Seite 354-364 |w (DE-627)NLM17958930X |x 1755-5949 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:1 |g day:13 |g month:01 |g pages:354-364 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cns.14010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 1 |b 13 |c 01 |h 354-364 | ||